Want to see ALLR full AI Analyst Report?
ALLR Stock Chart & Stats
$1.34
$0.04(3.36%)
At close: 4:00 PM EDT
$1.34
$0.04(3.36%)
Day’s Range― - ―
52-Week Range$0.77 - $2.06
Previous Close$1.21
Volume25.03K
Average Volume (3M)146.33K
Market Cap
$21.32M
Enterprise Value$15.83
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$22.29M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding15,910,724
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.25Price Target Upside664.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
U.S. Patent ProtectionThe U.S. patent strengthens Allarity’s intellectual-property position around stenoparib patient selection. Long exclusivity could support future partnering, regulatory differentiation, and commercial opportunities if the therapy and diagnostic achieve approval.
International IP FootprintPatent coverage across major regions broadens protection for the company’s precision-oncology approach. This may make the platform more defensible internationally and improve its strategic value in future licensing or collaboration discussions.
Improving Loss ProfileLosses have narrowed substantially from 2024 levels, indicating some reduction in the scale of operating losses. Although profitability remains distant, continued cost discipline could extend development runway if paired with progress in the pipeline.
Bears Say
Minimal Revenue BaseThe company lacks meaningful recurring commercial revenue and has no demonstrated growth trend. As a pre-commercial biotech, it remains dependent on financing, collaborations, or future product success to support research and corporate operations.
Persistent Cash BurnLarge ongoing cash outflows show that operations are not self-funding. Continued negative free cash flow may require additional capital before commercial milestones, creating execution risk and potential dilution if financing conditions remain challenging.
Elevated LeverageThe sharp increase in leverage materially weakens financial flexibility. Debt obligations can heighten refinancing pressure and compete with research spending, while any equity funding needed to address the balance sheet could dilute existing shareholders.
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.77 and its highest was $2.06 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $21.32M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 75 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.04.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,910,724 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went up 0.735%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$10.25
▲(664.93% Upside)
Technical Analysis
Ownership Overview
7.69% Insiders
1.90% Mutual Funds
0.62% Other Institutional Investors
88.71% Public Companies and
Individual Investors